Decagon Asset Management LLP Revance Therapeutics, Inc. Transaction History
Decagon Asset Management LLP
- $153 Billion
- Q2 2025
A detailed history of Decagon Asset Management LLP transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Decagon Asset Management LLP holds 26,300 shares of RVNC stock, worth $67,591. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,300Holding current value
$67,591% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding RVNC
# of Institutions
20Shares Held
10.1MCall Options Held
360KPut Options Held
0-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL423KShares$1.09 Million0.0% of portfolio
-
Rothschild & CO Asset Management Us Inc. New York, NY370KShares$949,9950.1% of portfolio
-
International Biotechnology Trust PLC London, X0289KShares$742,0251.12% of portfolio
-
Credit Suisse Ag Zurich, V8180KShares$462,9800.0% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...